ASX: EIQ RELEASE **1 December 2022**

ECHO IQ ANNOUNCES POSITIVE RESULTS FROM US CLINICAL STUDY

Highlights:

- **US based clinical efficacy study at Harvard Medical School's Beth Israel Deaconess Medical Center achieves primary study objective by successfully identifying a significant proportion of untreated aortic stenosis patients that fall within current treatment guidelines based on echocardiographic criteria.**
- **Out of 31,141 patients reviewed, ~5% identified with guideline-defined severe aortic stenosis.**
- **EchoSolv™ identified a separate cohort of patients, similar in size, outside current guidelines at similar high risk of mortality.**
- **This study demonstrates the potential impact of EchoSolv™ on streamlining clinical practice to better evaluate and manage patients with aortic stenosis.**
- **Results provide springboard to commercialisation and early revenues from US hospitals and healthcare providers.**

Sydney: AI and Medical Technology company Echo IQ ("the Company") (ASX:EIQ) is pleased to announce that it has achieved clear and positive results from its clinical effectiveness and validation study conducted at Beth Israel Deaconess Medical Center ("BIDMC"), a world-class teaching hospital of Harvard Medical School. These results are the first for Echo IQ from the important US market.

Overview/Background

Echo IQ entered into a study agreement with Beth Israel Deaconess Medical Center to assess the effectiveness of the Company's technology, as announced 27 July 2022. The study was conducted to retrospectively analyse patient records to evaluate Echo IQ's technology in detecting individuals with severe aortic stenosis as well as those with increased risk of death from the disease in a North American population.

Key Findings

This study was performed on 31,141 patient records from the hospital. Echo IQ's commercially-ready AI-backed technology, named "EchoSolv™, was applied to the BIDMC patient dataset. The key findings were:

- After excluding patients previously known to have been treated with an aortic valve replacement and compared to routine clinical interpretation, it rapidly and clearly identified a cluster of patients meeting guideline-definitions of severe aortic stenosis. This group accounted for a large (~5%) percentage of patients undergoing echocardiography at BIDMC.

ECHOIQ Limited ABN: 48 142 901 353
+61 2 9159 3719 / www.echoiq.ai
404/309 George Street, Sydney NSW 2000 Australia

- The study revealed that this cohort, meeting current echocardiographic guidelines for severe AS, received valve replacement in fewer than 50% of cases, consistent with known rates of treatment. Overall, the study showed that treatment for those with increased risk of death from aortic stenosis was received in only a quarter of cases identified by EchoSolv™.
- EchoSolv™ was also successful in identifying an additional group of individuals, similar in size to the first, with a similar pattern to those with severe aortic stenosis and having a substantially increased risk of death despite not meeting current treatment guidelines. Being able to identify this group of patients has the potential to assist clinicians in the important prioritization of patients that may benefit from more intense follow-up or aortic valve replacement.

Comments

Principal Investigator, Harvard Assistant Professor, and Director of the BIDMC Echocardiography Laboratory, Dr. Jordan B. Strom said: *"EchoSolv™ worked extremely well to identify individuals with severe aortic stenosis, despite needing minimal data inputs, suggesting its potential utility as a triage tool to identify patients at-risk and not-at-risk. Using EchoSolv™ in clinical practice could make a huge difference in our ability to identify those individuals who need timely evaluation."*

Echo IQ Chief Research & Strategy Officer, Prof. Geoff Strange said: *"This significant study demonstrates a number of important findings that support the value of EchoSolv™ in clinical practice. Firstly, the AI-backed technology identified a clear cohort of patients with a substantially increased risk of death. This has the capability to assist clinicians, physicians and heart care teams in delivering specialist care where it is needed most. The study also demonstrates the effectiveness of Echo IQ's solution across a broad, real-world US-demographic. This is expected to give users strong confidence in EchoSolv™ assessments. Echo IQ will be submitting the study for publication where full results can be viewed in detail."*

Echo IQ Chief Medical Advisor, Prof. David Playford said: *"These landmark results set a new standard in management of aortic stenosis. This system has significant implications for clinical practice and the future of echocardiography."*

Echo IQ Executive Chair, Andrew Grover said: *"This study is hugely important to the ongoing commercial development of Echo IQ. A number of US hospital groups with whom we are in advanced stages of discussion have been cautiously optimistic that this US-based study would yield positive results. Now that we can clearly show the efficacy of Echo IQ's technology in this kind of setting, we expect to see rapid commercial deployment of EchoSolv™ for retrospective use, increasing treatment options for patients as well as opportunities to treat for healthcare professionals."*

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:
Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.